Ligand-Bimodal Nanoparticle Conjugates for Non-Invasive CNS Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current contrast agents for brain imaging struggle to cross the blood-brain barrier effectively, limiting neuroimaging capabilities and often require invasive methods that cause neuronal injuries.
Innovation Solution
Development of ligand-bimodal nanoparticle conjugates comprising a polymeric matrix with magnetic particles and a near-infrared dye, conjugated with a ligand for a blood-brain barrier amino acid transporter, such as levodopa or 5-hydroxytryptophan, to facilitate non-invasive imaging of central nervous system tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional contrast agents are used for brain imaging, then imaging can be performed, but the agents cannot effectively cross the blood-brain barrier
Solution Approach 1:
The patent employs composite nanoparticle structures combining superparamagnetic iron oxide cores with polymeric shells, creating materials that exhibit both magnetic properties for MRI contrast and surface functionality for BBB targeting. This composite approach enables the agent to cross the blood-brain barrier while maintaining imaging capability.
Solution Approach 2:
The patent modifies key parameters of the contrast agent including particle size (reducing to nanoscale), surface charge, and surface chemistry to enable BBB penetration. By controlling particle diameter and surface functionalization, the agent achieves active transport across the barrier while retaining detectability.
2Reliability
If invasive methods are used to disrupt the blood-brain barrier, then imaging agents can enter the brain, but neuronal injuries occur
Solution Approach 1:
The patent uses ligands as intermediary molecules that mediate the interaction between the contrast agent and the blood-brain barrier. These ligands bind to specific transport receptors on the barrier, facilitating gentle, receptor-mediated transcytosis of the nanoparticle without mechanical disruption or chemical damage to neuronal tissue.
Solution Approach 2:
The patent replaces invasive mechanical disruption methods with a biochemical transport mechanism. Instead of physically breaking the barrier, the agent uses ligand-receptor binding and cellular transport processes to cross the barrier intact, eliminating mechanical damage to neurons.
3Reliability
If the nanoparticle is made smaller to cross the blood-brain barrier, then BBB penetration improves, but imaging sensitivity may decrease
Solution Approach 1:
The patent combines multiple imaging modalities within a single nanoparticle platform, integrating MRI contrast functionality with optical imaging capabilities. This dual-modal approach allows the small nanoparticle to provide sufficient signal for both magnetic resonance detection and optical detection, compensating for the reduced size.
Solution Approach 2:
The nanoparticle is designed with multi-functionality, serving simultaneously as a BBB targeting vehicle, an MRI contrast agent, and an optical imaging probe. This universal design enables the small particle to fulfill multiple roles, including providing adequate imaging signal through combined modalities while maintaining the size necessary for barrier penetration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates enable safe, non-invasive imaging of dopaminergic, noradrenergic, and serotonergic neurons by crossing the blood-brain barrier, providing detailed visualization of central nervous system tissue without causing neuronal injuries, using techniques like MRI and fluorescence resonance energy transfer imaging.
Implementation Method 1
one or more magnetic particles disposed within the polymeric matrix or conjugated to an outer surface of the polymeric matrix
Implementation Method 2
a near-infrared dye disposed within the polymeric matrix
Implementation Method 3
a ligand for a blood-brain barrier amino acid transporter, the ligand conjugated to the outer surface of the bimodal nanoparticle
Data Source
AI summary
Ligand-bimodal nanoparticle conjugates capable of crossing the blood-brain barrier are disclosed. Methods of making and using the conjugates also are disclosed. The bimodal nanoparticle includes a polymeric matrix, one or more magnetic particles disposed within the polymeric matrix or conjugated to an outer surface of the polymeric matrix, and a dye disposed within the polymeric matrix. A ligand for a blood-brain barrier amino acid transporter is conjugated to the outer surface of the bimodal nanoparticle.